Skip to main content
OpenTrials
Completed

NCT Number: NCT07032337

Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder

Newly diagnosed NMOSD patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuromyelitis Optica Spectrum Disorder (NMOSD) Autoimmune Diseases Autoimmune Diseases of the Nervous System Cranial Nerve Diseases Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Eye Diseases Immune System Diseases Myelitis, Transverse Nervous System Diseases Neuromyelitis Optica Optic Nerve Diseases Optic Neuritis

Sex eligibility

All sexes

Study type

Observational

About this study

From 2011 to 2022, newly diagnosed NMOSD patients who had not previously claimed NMOSD. Exclusion criteria were history of cancer or had used ISTs (excluding steroids) prior to the NMOSD diagnosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • From 2011 to 2022, newly diagnosed NMOSD patients..

Exclusion criteria

  • Patients had a history of cancer
  • Patients had used ISTs (excluding steroids) prior to the NMOSD diagnosis.

Treatment and study plan

Primary outcomes

  1. Relapse

    Time frame: 1 year

    Relapses were identified when patients were treated with one of the following interventions: intravenous steroids, immunoglobulin therapy, or plasma exchange.

Secondary outcomes

  1. Safety outcomes

    Time frame: 6 months after start of ISTs

    Incidence of serious infection, fracture, cancer, myocardial infarction, stroke, depression, anxiety, dementia, and Parkinson's disease which defined as presence of ICD-10 codes.

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder: A Target Trial Emulation Study

Important dates

Study start
2011
Primary completion
2022
Study completion
2022
First posted
Jun 23, 2025
Registry last updated
Jun 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.